Richard Law
Stock Analyst at Goldman Sachs
(2.31)
# 2,255
Out of 4,944 analysts
65
Total ratings
35.48%
Success rate
3.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $18.48 | +62.34% | 4 | Aug 7, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $74 → $82 | $55.79 | +46.98% | 4 | Aug 6, 2025 | |
| ARQT Arcutis Biotherapeutics | Initiates: Neutral | $18 | $15.41 | +16.85% | 1 | Jul 25, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $5.32 | +238.35% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $5.78 | -48.10% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.06 | +324.84% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $25.02 | +23.90% | 3 | May 9, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $40.11 | -25.21% | 1 | Apr 8, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $28 → $24 | $13.63 | +76.08% | 6 | Feb 13, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $66.75 | +9.36% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $4.35 | +152.87% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $17.83 | +163.60% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $59.44 | +6.00% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $40.95 | -9.65% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $11.11 | +584.07% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $3.06 | +357.52% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $6.93 | +780.23% | 4 | May 8, 2023 |
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $18.48
Upside: +62.34%
MoonLake Immunotherapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $74 → $82
Current: $55.79
Upside: +46.98%
Arcutis Biotherapeutics
Jul 25, 2025
Initiates: Neutral
Price Target: $18
Current: $15.41
Upside: +16.85%
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $5.32
Upside: +238.35%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.78
Upside: -48.10%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.06
Upside: +324.84%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $25.02
Upside: +23.90%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $40.11
Upside: -25.21%
Mineralys Therapeutics
Feb 13, 2025
Maintains: Buy
Price Target: $28 → $24
Current: $13.63
Upside: +76.08%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $66.75
Upside: +9.36%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $4.35
Upside: +152.87%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $17.83
Upside: +163.60%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $59.44
Upside: +6.00%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $40.95
Upside: -9.65%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $11.11
Upside: +584.07%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $3.06
Upside: +357.52%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $6.93
Upside: +780.23%